Sanara MedTech Inc. 8-K

What Happened Sanara MedTech Inc. (SMTI) announced in an 8-K that it and The Catalyst Group, Inc. mutually terminated their Transaction Advisory Services Agreement, effective June 2, 2026. The original Services Agreement was entered into effective March 1, 2023 (signed March 20, 2023). The termination follows Sanara’s strategic shift to focus on soft tissue repair and bone fusion products for the surgical market. No fee or penalty was paid in connection with the termination.

Key Details

• Agreement parties: Sanara MedTech and The Catalyst Group, Inc.; Catalyst’s founder/managing partner is Sanara’s Chairman, Ronald T. Nixon.
• Dates: Services Agreement effective March 1, 2023 (entered March 20, 2023); Mutual Termination Agreement effective June 2, 2026.
• Ownership/related party: Catalyst and affiliates collectively beneficially own >5% of Sanara’s common stock.
• Post-termination terms: Certain covenants from the Services Agreement (including indemnification and confidentiality) remain in force; no termination fee or penalty was paid.

Why It Matters The termination removes a formal advisory relationship with a related-party firm as Sanara refocuses its business toward surgical soft tissue repair and bone fusion products. For investors, this clarifies the company’s strategic direction and eliminates ongoing advisory obligations under that agreement, while preserving confidentiality and indemnity protections. The filing is factual and does not announce financial results, new financing, or other compensation tied to the termination.